XNAS
IMNN
Market cap4mUSD
Oct 08, Last price
1.07USD
1D
-6.14%
1Q
-47.03%
Jan 2017
-99.87%
Name
Imunon Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
67.02%
Rev. gr., 5y
0.00%
Revenues
0
Net income
-14m
L-22.15%
CFO
-14m
L-26.30%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Imunon, Inc. is a biotechnology enterprise operating at the clinical development stage, dedicated to the advancement and commercialization of innovative DNA-centric immunotherapeutic agents, vaccines, and targeted chemotherapy treatments. Its product pipeline prominently features GEN-1, a DNA-based immunotherapy specifically designed for the localized management of ovarian cancer. Alongside this, the company is developing ThermoDox, a proprietary liposomal formulation of doxorubicin that is activated by heat, currently being explored for various oncological indications. Beyond its specific product candidates, Imunon also possesses two early-stage platform technologies, which serve as foundational tools for crafting additional nucleic acid-based immunotherapies, vaccines, and diverse anti-cancer DNA or RNA therapeutics. Founded in 1982 and headquartered in Lawrenceville, New Jersey, the company was formerly recognized as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Key people
David Gaiero
Chief Financial Officer · since 2024
Sebastien Hazard
Executive Vice President, Chief Medical Officer · since 2023
Susan Eylward
General Counsel, Corporate Secretary · since 2024
Michael Tardugno
Executive Chairman of the Board · since 2022
Douglas Faller
Chief Medical Officer · since 2025
President, Chief Executive Officer, Director · since 2024
Donald Braun
Independent Director · since 2015
Independent Director · since 2022
Frederick Fritz
Independent Director · since 2011
Independent Director · since 2021
Legal address
c/o United Corporate Services, Inc., 874 Walker RD STE C
Dover, DE 19904
US
Dover, DE 19904
US
Headquarters
Suite 100, 997 Lenox Drive
Lawrenceville, NJ 08648
US
Lawrenceville, NJ 08648
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||